Cite
HARVARD Citation
Glintborg, B. et al. (2022). One‐Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10, 000 Treatment Courses. Arthritis care & research. 74 (5), pp. 748-758. [Online].